|
1
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu Q, Yang Z, Nie Y, Shi Y and Fan D:
Multidrug resistance in cancer chemotherapeutics: mechanisms and
lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dean M, Hamon Y and Chimini G: The human
ATP-binding cassette (ABC) transporter superfamily. J Lipid Res.
42:1007–1017. 2001.PubMed/NCBI
|
|
4
|
Breier A, Gibalova L, Seres M, Barancik M
and Sulova Z: New insight into p-glycoprotein as a drug target.
Anticancer Agents Med Chem. 13:159–170. 2013. View Article : Google Scholar
|
|
5
|
Palmeira A, Sousa E, Vasconcelos MH and
Pinto MM: Three decades of P-gp inhibitors: skimming through
several generations and scaffolds. Curr Med Chem. 19:1946–2025.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee CH: Reversing agents for ATP-binding
cassette drug transporters. Methods Mol Biol. 596:325–340. 2010.
View Article : Google Scholar
|
|
7
|
Wang YS, Liao Z, Li YA, et al: New
megastigmane diglycoside from Litsea glutinosa (Lour. ) C B Rob J
Brazil Chem Soc. 22:2234–2238. 2011. View Article : Google Scholar
|
|
8
|
Ansari MT, Saify ZS and Sultana N: Malaria
and artemisinin derivatives: an updated review. Mini-Rev Med Chem.
13:1879–1902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun J, Yeung CA, Co NN, et al: Clitocine
reversal of P-glycoprotein associated multi-drug resistance through
downregulation of transcription factor NF-κB in R-HepG2 cell line.
PLoS One. 7:e407202012. View Article : Google Scholar
|
|
10
|
Zhang DM, Shu C, Chen JJ, et al: BBA, a
derivative of 23-hydroxybetulinic acid, potently reverses
ABCB1-mediated drug resistance in vitro and in vivo. Mol Pharm.
9:3147–3159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang DM, Li YJ, Shu C, et al:
Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse
resistance of HepG2/ADM and MCF-7/ADR cells. Anticancer Drugs.
24:441–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao N, Liu DL, Li YJ, et al: B5H7, a
morpholine derivative of 23-hydroxybetulinic acid, reverses
doxorubicin resistance in HepG2/ADM. J Cancer Res Updates. 3:59–66.
2014.
|
|
13
|
Liu DL, Li YJ, Yao N, et al: Acerinol, a
cyclolanstane triterpenoid from Cimicifuga acerina, reverses
ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR
cells. Eur J Pharmacol. 733:34–44. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu GS, Guo JJ, Bao JL, et al: Anti-cancer
properties of triterpenoids isolated from Ganoderma lucidum
(Review). Expert Opin Inv Drug. 22:981–992. 2013. View Article : Google Scholar
|
|
15
|
Guan SH, Xia JM, Yang M, Wang XM, Liu X
and Guo DA: Cytotoxic lanostanoid triterpenes from Ganoderma
lucidum. J Asian Nat Prod Res. 10:695–700. 2008. View Article : Google Scholar
|
|
16
|
Wu G, Qian Z, Guo J, et al: Ganoderma
lucidum extract induces G1 cell cycle arrest, and apoptosis in
human breast cancer cells. Am J Chinese Med. 40:631–642. 2002.
View Article : Google Scholar
|
|
17
|
Wang J, Chan JY, Fong CC, Tzang CH, Fung
KP and Yang M: Transcriptional analysis of doxorubicin-induced
cytotoxicity and resistance in human hepatocellular carcinoma cell
lines. Liver Int. 129:1338–1347. 2009. View Article : Google Scholar
|
|
18
|
Wu GS, Lu JJ, Gu JJ, et al: Ganoderic acid
DM, a natural triterpenoid, induces DNA damage, G1 cell cycle
arrest and apoptosis in human breast cancer cells. Fitoterapia.
83:408–414. 2012. View Article : Google Scholar
|
|
19
|
Wang YL, Zhang XQ, Wang GC and Ye WC:
Chemical constituents of the fruiting bodies of Ganoderma lucidum.
Jiangsu Pharm Clin Res. 14:349–351. 2006.
|
|
20
|
Chan JY, Chu AC, Fung KP, et al:
Inhibition of P-glycoprotein expression and reversal of drug
resistance of human hepatoma HepG2 cells by multidrug resistance
gene (mdr1) antisense RNA. Life Sci. 67:2117–2124. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fu LW, Zhang YM, Liang YJ, Yang XP and Pan
QC: The multidrug resistance of tumor cells was reversed by
tetrandrine in vitro and in xenografts derived from human breast
adenocarcinoma MCF-7/adr cells. Eur J Cancer. 38:418–426. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Massart C, Gibassier J, Lucas C, Pourquier
P and Robert J: Expression of the MDR1 gene in five human cell
lines of medullary thyroid cancer and reversal of the resistance to
doxo-rubicine by ciclosporin A and verapamil. B Cancer. 83:39–45.
1996.
|
|
23
|
Aller SG, Yu J, Ward A, et al: Structure
of P-glycoprotein reveals a molecular basis for poly-specific drug
binding. Science. 323:1718–1722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sharom FJ: Complex interplay between the
P-glycoprotein multidrug efflux pump and the membrane: its role in
modulating protein function. Front Oncol. 4:412014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu CP, Ohnuma S and Ambudkar SV:
Discovering natural product modulators to overcome multidrug
resistance in cancer chemotherapy. Curr Pharm Biotechnol.
12:609–620. 2011. View Article : Google Scholar
|
|
26
|
Li WD, Zhang BD, Wei R, Liu JH and Lin ZB:
Reversal effect of Ganoderma lucidum polysaccharide on multidrug
resistance in K562/ADM cell line. Acta Pharmacol Sin. 29:620–627.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang PP, Xu DJ, Huang C, Wang WP and Xu
WK: Astragaloside IV reduces the expression level of P-glycoprotein
in multidrug-resistant human hepatic cancer cell lines. Mol Med
Rep. 9:2131–2137. 2014.PubMed/NCBI
|
|
28
|
Shi Z, Peng XX, Kim IW, et al: Erlotinib
(Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B
member 1 and ATP-binding cassette subfamily G member 2-mediated
drug resistance. Cancer Res. 67:11012–11022. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mi YJ, Liang YJ, Huang HB, et al: Apatinib
(YN968D1) reverses multidrug resistance by inhibiting the efflux
function of multiple ATP-bindingcassette transporters. Cancer Res.
70:7981–7991. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dai CL, Tiwari AK, Wu CP, et al: Lapatinib
(Tykerb, GW572016) reverses multidrug resistance in cancer cells by
inhibiting the activity of ATP-binding cassette subfamily B member
1 and G member 2. Cancer Res. 68:7905–7914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martin C, Berridge G, Mistry P, Higgins C,
Charlton P and Callaghan R: The molecular interaction of the high
affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol.
128:403–411. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kang MH, Figg WD, Ando Y, et al: The
P-glycoprotein antagonist PSC 833 increases the plasma
concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of
paclitaxel. Clin Cancer Res. 7:1610–1617. 2001.PubMed/NCBI
|
